Retraction: Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against mycobacterium tuberculosis infection (PLoS ONE (2013) 8:4 (e61135) DOI: 10.1371/journal.pone.0061135);Enhanced Immune Response and Protective Effects of Nano-chitosan-based DNA Vaccine Encoding T Cell Epitopes of Esat-6 and FL against Mycobacterium Tuberculosis Infection

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Feng, Ganzhu ^a   Jiang, Qingtao ^a   Xia, Mei ^a   Lu, Yanlai ^a   Qiu, Wen ^a   Zhao, Dan ^a   Lu, Liwei ^b   Peng, Guangyong ^c   Wang, Yingwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CHITOSAN; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; EPITOPE; FMS LIKE TYROSINE KINASE 3 LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; NANOPARTICLE; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CD135 ANTIGEN; CYTOKINE; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; LIGAND; RECOMBINANT PROTEIN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNE RESPONSE; MESANGIUM CELL; MOUSE; NONHUMAN; PARTICLE SIZE; RAT; RECOMBINANT PLASMID; SPLEEN CELL; TUBERCULOSIS; ZETA POTENTIAL; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; CYTOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MYCOBACTERIUM TUBERCULOSIS; PHYSIOLOGY; SPLEEN;

MUS; MYCOBACTERIUM TUBERCULOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CELL COUNT; CELL PROLIFERATION; CHITOSAN; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; IMMUNIZATION; INTERFERON-GAMMA; LIGANDS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; NANOPARTICLES; PARTICLE SIZE; RECOMBINANT PROTEINS; SPLEEN; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUBERCULOSIS; VACCINES, DNA;

EID: 84876579173     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0303549     Document Type: Erratum

References (52)

1. Dye C, Williams BG, (2010) The population dynamics and control of tuberculosis. Science 14: 856-861.
2. Hussey G, Hawkridge T, Hanekom W, (2007) Childhood tuberculosis: old and new vaccines. Paediatr Respir Rev 8: 148-154.
3. Begum D, Umemura M, Yahagi A, Okamoto Y, Hamada S, et al. (2009) Accelerated induction of mycobacterial antigen-specific CD8+ T cells in the Mycobacterium tuberculosis-infected lung by subcutaneous vaccination with Mycobacterium bovis bacille Calmette-Guérin. Immunology 128: 556-563.
4. Ganguly N, Giang PH, Gupta C, Basu SK, Siddiqui I, et al. (2008) Mycobacterium tuberculosis secretory proteins CFP-10, ESAT-6 and the CFP-10: ESAT-6 complex inhibit lipopolysaccharide-induced NF-κB transactivation by downregulation of reactive oxidative species (ROS) production. Immunol Cell Biol 86: 98-106.
5. Brodin P, Rosenkrand I, Andersen P, Cole ST, Brosch R, (2004) ESAT-6 proteins: protective antigens and virulence factors? Trend Microbiol 12: 500-508.
6. Majlessi L, Brodin P, Brosch R, Rojas MJ, Khun H, et al. (2005) Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J Immunol 174: 3570-3579.
7. Sette A, Livingston B, McKinney D, Appella E, Fikes J, et al. (2001) The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 29: 271-276.
8. Gurunathan S, Klinman DM, Seder RA, (2000) DNA vaccine: immunology, application, an optimization. Annu Rev mmunol 18: 927-974.
9. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C, (2001) Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 22: 41-47.
10. Toliver-Kinsky TE, Lin CY, Herndon DN, Sherwood ER, (2003) Stimulation of hematopoiesis by the fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice. Infect Immun 71: 3058-3067.
11. Zhou Q, Wang F, Yang F, Wang Y, Zhang X, et al. (2010) Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant. Vaccine 28: 1357-1362.
12. Xu J, Xu W, Chen X, Zhao D, Wang Y, (2008) Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine 26: 4519-4525.
13. Cui Z, Mumper RJ, (2001) Chitosan-based nanoparticles for topical genetic immunization. J Control Release 75: 409-419.
14. Illum L, Jabbal-Gill I, Hinchcliffe M, Fishe AN, Davis SS, (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51: 81-96.
15. Behrens I, Pena AI, Alonso MJ, Kissel T, (2002) Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle absorption and transport. Pharm Res 19: 1185-1193.
16. Huang M, Khor E, Lim LY, (2004) Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm Res 21: 344-353.
17. Zheng Y, Kovacs JR, Gawalt ES, Hongmei Shen, Meng WS, (2006) Characterization of particles fabricated with poly (D, L-lactic-co-glycolic acid) and an ornithine-histidine peptide as carriers of oligodeoxynucleotide for delivery into primary dendritic cells. J Biomater Sci Polym Ed 17: 1389-1403.
18. Leong KW, Mao HQ, Truong-Le VL, Roy K, Walsh SM, et al. (1998) DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release 53: 183-193.
19. Slütter B, Plapied L, Fievez V, Sande MA, des Rieux A, et al. (2009) Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 138: 113-121.
20. Yang Y, Chen J, Li H, Wang Y, Xie Z, et al. (2007) Porcine interleukin-2 gene encapsulated in chitosan nanoparticles enhances immune response of mice to piglet paratyphoid vaccine. Comp Immunol Microbiol Infect Dis 30: 19-32.
21. Neimert-Andersson T, Hällgren AC, Andersson M, Langebäck J, Zettergren L, et al. (2011) Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine 29 (48):: 8965-8973.
22. Gao H, Li K, Yu S, Xiong S, (2009) A novel DNA vaccine containing multiple TB-specific epitopes cast in a natural structure elicits enhanced Th1 immunity compared with BCG. Microbiol Immunol 53: 541-549.
23. Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, et al. (2001) Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 166: 5366-5373.
24. Teutschbein J, Schumann G, Möllmann U, Grabley S, Cole ST, et al. (2009) A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of Mycobacterium tuberculosis. Microbiol Res 164: 253-259.
25. Kaufmann SH, Hussey G, Lambert PH, (2012) New vaccines for tuberculosis. Lancet (2010) 375: 2110-2119.
26. Li L, Qiao D, Li Q, Zhang X, Lao S, et al. (2012) Distinct polyfunctional CD4 (+) T cell responses to BCG, ESAT-6 and CFP-10 in tuberculous pleurisy. Tuberculosis (Edinb) 92 (1):: 63-71.
27. Chatterjee S, Dwivedi VP, Singh Y, Siddiqui I, Sharma P, et al. (2011) Early secreted antigen ESAT-6 of Mycobacterium tuberculosis promotes protective T helper 17 cell responses in a toll-like receptor-2-dependent manner. PLoS Pathog 7 (11):: e1002378.
28. Latorre I, Altet N, de Souza-Galvão M, Ruiz-Manzano J, Lacoma A, et al. (2012) Specific Mycobacterium tuberculosis T cell responses to RD1-selected peptides for the monitoring of anti-tuberculosis therapy. Scand J Immunol 75 (1):: 77-84.
29. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, et al. (2011) Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29 (1):: 2100-2109.
30. Deng YH, Sun Z, Yang XL, Bao L, (2010) Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis. Scand J Immunol 72 (4):: 332-338.
31. Shen H, Wang C, Yang E, Xu Y, Liu W, et al. (2010) Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice. Microbiol Immunol 54 (8):: 435-441.
32. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, et al. (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine 28 (20):: 3571-3581.
33. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P, (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68: 791-795.
34. Yu F, Wang J, Dou J, Yang H, He X, et al. (2012) Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine 8 (8):: 1337-1344.
35. Gupta UD, Katoch VM, McMurry DN, (2007) Current status of TB vaccines. Vaccine 25: 3742-3751.
36. De Groot AS, McMurry J, Marcon L, Franco J, Rivera D, et al. (2005) Deveoping an epitope-driven tuberculosis (TB) vaccine. Vaccine 23: 2121-2131.
37. Sette A, Fikes J, (2003) Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opin Immunol 15: 461-470.
38. Qingtao J, Jing Z, Xia C, Mei X, Yanlai L, et al. (2012) A novel recombinant DNA vaccine encoding ESAT-6 T cell epitopes and FL induces efficient protection against mycobacterium tuberculosis challenge. J Biom Res (In press).
39. Jones GJ, Gordon SV, Hewinson RG, Vordermeier HM, (2010) Screening of predicted secreted antigens from Mycobacterium bovis reveals the immunodominance of the ESAT-6 protein family. Infect Immun 78 (3):: 1326-1332.
40. Aagaard CS, Hoang TT, Vingsbo-Lundberg C, Dietrich J, Andersen P, (2009) Quality and vaccine efficacy of CD4+ T cell responses directed to dominant subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J Immunol 183 (4):: 2659-2668.
41. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J, (2007) Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1. J Immunol 179 (6):: 3973-3981.
42. Vila A, Sánchez A, Janes K, Behrens I, Kissel T, et al. (2004) Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 57: 123-131.
43. Wang F, He XW, Jiang L, Ren D, He Y, et al. (2006) Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 24: 2017-2026.
44. Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W, (2005) Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26: 5727-5736.
45. Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP, (2008) Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm 354: 235-241.
46. Bal SM, Slütter B, Verheul R, Bouwstra JA, Jiskoot W, (2012) Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci 45 (4):: 475-481.
47. Chua BY, Al Kobaisi M, Zeng W, Mainwaring D, Jackson DC, (2012) Chitosan microparticles and nanoparticles as biocompatible delivery vehicles for peptide and protein-based immunocontraceptive vaccines. Mol Pharm 9 (1):: 81-90.
48. Bennekov T, Dietrich J, Rosenkrands I, Stryhn A, Doherty TM, et al. (2006) Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol 36 (12):: 3346-3355.
49. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, et al. (2006) Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 177 (9):: 6353-6360.
50. Borsuk S, Newcombe J, Mendum TA, Dellagostin OA, McFadden J, (2009) Identification of proteins from tuberculin purified protein derivative (PPD) by LC-MS/MS. Tuberculosis (Edinb) 89: 423-430.
51. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
52. McCormick S, Santosuosso M, Small CL, Shaler CR, Zhang X, et al. (2008) Mucosally delivered dendritic cells activate T cells independently of IL-12 and endogenous APCs. J Immunol 181: 2356-2367.